PipelineReview.com8h
Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
PRINCETON, NJ, USA & TOKYO, Japan I2, 2024 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd.
PipelineReview.com6h
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
NEW YORK, NY, USA I October 22, 2024 I SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into ...
PipelineReview.com8h
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
AACHEN, Germany I October 22, 2024 I Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for ...
PipelineReview.com8h
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
ROCKVILLE, MD & DEERFIELD, IL, USA I2, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, ...